Wednesday, July 8, 2026

biotech · Parkinson Disease · Amyotrophic Lateral Sclerosis · DNLI

Denali Therapeutics

NovaPharmaNews editorial coverage mentioning Denali Therapeutics — regulatory, clinical, and market analysis.

161 Oyster Point Blvd, South San Francisco, California 94080, US HQ
2015 Founded
567 Employees
Public company Type
DNLI · NYSE Ticker
Company details
Status
Public
HQ
161 Oyster Point Blvd, South San Francisco, California 94080, US
Founded
2015
Employees
567
Programs
23
Drugs
10
Patents
42
Intelligence · Coverage

News & analysis

NovaPharmaNews articles mentioning Denali Therapeutics — regulatory, clinical, and market coverage.

NovaPharmaNews editorial coverage mentioning Denali Therapeutics — regulatory, clinical, and market analysis.

No coverage yet

We have not published news or analysis mentioning Denali Therapeutics yet.

Back to company overview →